Follow us...

 

Search News Archives

Monthly Newsletter

 

Lab Bulletin May Newsletter

view the latest issue

Subscribe

News Channels

 

New Laboratory Products

 

Lab News

 

Microscopy & Image Analysis

 

Separation Science

 

Research & Case Studies

 

Literature

 

Videos

 

Events | Webinars

 

 

 

Conferences | Events

New Webinar: Optimizing Analytics for Biosimilars

publication date: May 27, 2016
 | 
author/source: Sartorius Group

How Providing Comprehensive Data Can Accelerate Drug Development

sartoriusSartorius Stedim BioOutsource today announced that its scientific experts will be presenting a live webinar about optimizing biosimilar analysis on Thursday, June 2, at 3 pm BST, 10 am EDT. The webinar is essential listening for researchers who want to understand how to select optimal clones and processes to accelerate development of their biosimilars.

During the one-hour webinar, Dr. Martin De Cecco, and Dr. Terry Gray will explore the impact of differing glycan structures on antibody function using a case study comparing biosimilar infliximab to the innovator molecule Remicade®. Drawing on real-life examples, both experts will discuss a variety of orthogonal methods, including glycan analysis by LC-MS, CD16a and SPR binding, as well as ADCC activity that will highlight the benefits of performing combined structural and functional analysis. They will also be discussing the importance of choosing appropriate analytical assays at each stage of the product’s development and how utilizing a comprehensive testing package can provide evidence suitable for regulatory submissions to enable biosimilars to enter clinical programs more rapidly. 

To register for this informative webinar and receive a recording to listen to on demand, scientists should click the link:

http://www.business-review-webinars.com/webinar/Pharma/Orthogonal_Analytics_for_Biosimilars-g2zTPRKH

Dr. Daniel Galbraith, Chief Scientific Officer of Sartorius Stedim BioOutsource, stated: “The complex nature of monoclonal antibodies often results in differences between the biosimilar and innovator molecule and the key to regulatory acceptance is understanding the potential clinical significance of those residual differences. We’re delighted to be hosting a webinar during which our experts will explain how generating comprehensive characterization data for the regulators can overcome reservations about a new monoclonal, to deliver faster and more cost-effective biosimilar drug development.”


more about sartorius


more news from sartorius



If you have not logged into the website then please enter your details below.



 

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd

 


Promotions

 

Media Partners